Q1 Earnings Forecast for Zai Lab Issued By Leerink Partnrs

Zai Lab Limited (NASDAQ:ZLAB) – Leerink Partnrs issued their Q1 2025 earnings estimates for Zai Lab in a research report issued to clients and investors on Thursday, February 20th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($0.51) per share for the quarter. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Leerink Partnrs also issued estimates for Zai Lab’s Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Separately, Cantor Fitzgerald upgraded shares of Zai Lab to a “strong-buy” rating in a research report on Wednesday, February 5th.

Zai Lab Price Performance

Shares of ZLAB opened at $33.91 on Monday. Zai Lab has a one year low of $13.48 and a one year high of $36.60. The company has a market cap of $3.71 billion, a P/E ratio of -12.24 and a beta of 1.02. The firm has a 50 day simple moving average of $27.17 and a two-hundred day simple moving average of $25.57.

Institutional Trading of Zai Lab

A number of hedge funds and other institutional investors have recently modified their holdings of ZLAB. Janus Henderson Group PLC grew its stake in shares of Zai Lab by 34.2% in the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock worth $211,488,000 after purchasing an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Zai Lab by 18.4% during the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after purchasing an additional 1,312,115 shares during the period. FMR LLC raised its holdings in shares of Zai Lab by 749.1% during the fourth quarter. FMR LLC now owns 5,475,505 shares of the company’s stock valued at $143,403,000 after purchasing an additional 4,830,646 shares during the period. RTW Investments LP acquired a new position in shares of Zai Lab during the fourth quarter valued at about $65,714,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Zai Lab by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company’s stock valued at $61,653,000 after purchasing an additional 548,378 shares during the period. Institutional investors own 41.65% of the company’s stock.

Insiders Place Their Bets

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 13.88% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.